Device Trial Radar · NCT00401466
Remote Follow-up of Patients Receiving Implantable Cardioverter Defibrillator for Prophylactic Therapy
Last checked: Nov 20, 2026Latest source record: Jan 17, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
155
Actual
Start
Jan 2004
Primary completion
Jul 2008
Study completion Jul 2008
Sponsor
- Lead sponsor
- Biotronik SE & Co. KGNot on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 20, 2006
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Health services research
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The completed MADIT II study has shown that implantation of a cardioverter-defibrillator (ICD) in patients with a reduced left ventricular ejection fraction and a prior myocardial infarction reduces death from any cause. The probability of the first therapy due to ventricular tachyarrhythmia was about 34% within 3 years. With a 3-month ICD-follow-up scheme, as it is in the standard ICD therapy, the majority of patients is followed more closely than necessary with respect to anti-tachyarrhythmia ICD therapy. A Home Monitoring (HM) function has been integrated into several ICD models from Biotronik (Berlin , Germany), for close remote monitoring of ICD patients. The HM function may substitute in-clinic follow-up controls. The objective of our study is to compare a standard 3-month follow-up scheme and a 12-month follow-up scheme using HM in ICD recipients with the "MADIT II indications". The comparison should be made with respect to the difference in follow-up burden and the associated costs, and regarding possible impact of the remote follow-up via HM on all cause mortality, hospitalization, and patients' quality of life.
Conditions
- Ventricular Fibrillation
- Ventricular Tachycardia
Interventions
Implantable Cardioverter DefibrillatorDevice
ICD with Biotronik Home Monitoring capability
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of follow-up visitsTime frame: 27 months
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
Institute of clinical and experimental medicine
Prague, Czechia
Hospital Na Homolce
Prague, Czechia
Zentralklinik Bad Berka
Bad Berka, Germany
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.